- Home
- GILD vs SNY Comparison
GILD vs SNY Comparison
Compare GILD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- SNY
- Stock Information
- Founded
- GILD 1987
- SNY 1994
- Country
- GILD United States
- SNY France
- Employees
- GILD N/A
- SNY N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- GILD Health Care
- SNY Health Care
- Exchange
- GILD Nasdaq
- SNY Nasdaq
- Market Cap
- GILD 147.6B
- SNY 119.4B
- IPO Year
- GILD 1992
- SNY N/A
- Fundamental
- Price
- GILD $127.67
- SNY $50.02
- Analyst Decision
- GILD Buy
- SNY Buy
- Analyst Count
- GILD 22
- SNY 4
- Target Price
- GILD $123.45
- SNY $61.50
- AVG Volume (30 Days)
- GILD 7.6M
- SNY 2.3M
- Earning Date
- GILD 10-30-2025
- SNY 10-24-2025
- Dividend Yield
- GILD 2.48%
- SNY 3.19%
- EPS Growth
- GILD 6514.05
- SNY 105.93
- EPS
- GILD 6.42
- SNY 8.67
- Revenue
- GILD $29,087,000,000.00
- SNY $53,890,648,839.00
- Revenue This Year
- GILD $3.05
- SNY $2.37
- Revenue Next Year
- GILD $3.29
- SNY $6.51
- P/E Ratio
- GILD $19.85
- SNY $5.77
- Revenue Growth
- GILD 2.79
- SNY N/A
- 52 Week Low
- GILD $88.57
- SNY $44.62
- 52 Week High
- GILD $128.70
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- GILD 60.74
- SNY 49.09
- Support Level
- GILD $124.49
- SNY $49.14
- Resistance Level
- GILD $128.25
- SNY $50.61
- Average True Range (ATR)
- GILD 3.43
- SNY 0.76
- MACD
- GILD 0.17
- SNY -0.20
- Stochastic Oscillator
- GILD 91.36
- SNY 31.90
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.